Val-chum, Limited Partnership

Centre Hospitalier De L'universite De Montreal

Alexandre Prat

Romain Cayrol

Nathalie Arbour

Simone Terouz

Soufiane Ghannam

Igal Ifergan

Hania Kebir

Catherine Larochelle

Novel antibodies directed against Dual Ig domain containing cell adhesion molecule (DICAM) are described. These anti-DICAM antibodies are capable of detecting DICAM by Western blot and/or flow cytometry, blocking the interaction between DICAM and its ligand &#x3b1;V&#x3b2;3 integrin, and/or blocking the migration of inflammatory cytokine-secreting T17 lymphocytes across the blood brain barrier. Uses of these antibodies or compositions comprising same for the diagnosis, prevention and/or treatment of autoimmune/inflammatory conditions, such as neuroinflammatory conditions, and for the targeting, identification and selection of inflammatory cytokine-secreting T17 lymphocytes or precursor thereof are also disclosed.

DICAM-specific antibodies and uses thereof

Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed.

Treatment of neuroinflammatory conditions using antibodies directed against MCAM

Methods, uses, agents and compositions useful for the prevention, treatment and/or diagnosis of neuroinflammatory conditions such as multiple sclerosis and spinal cord injury based on the modulation of nerve injury-induced protein-1 (Ninjurin-1) are disclosed.

Ninjurin-1 modulation and uses thereof

MCAM modulation and uses thereof

Growing community of inventors

Outremont, Canada

Alexandre Prat